Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
What the film says
Hairy cell leukemia is rare and usually gentle; most people respond to a week of chemotherapy and stay well for years. But a variant form shrugs it off, and once targeted drugs fail, survival is a couple of years.
The idea: turn CAR T cells, proven in other B-cell leukemias, on this one.
Hairy cells are brightly coated in a protein called CD22. The National Cancer Institute team that built the first anti-CD22 drug for this disease now fits a patient's own T cells with a receptor for it. After chemotherapy makes room, one infusion goes in.
Robert Kreitman leads it at the NIH Clinical Center in Bethesda, for adults out of standard options, asking what dose is safe. Public record; not medical advice.
Sources behind this film
Rare, indolent; most respond to purine analog chemotherapy; Variant and high-risk classic cases respond poorly; survival under three years after cladribine-rituximab failure; Brightly CD22-positive; NCI team built the first anti-CD22 drug for HCL (moxetumomab pasudotox, FDA-approved 2018) (+2 more lines)
Kreitman RJ. Leukemia, 2018
NCI team built the first anti-CD22 drug for HCL (moxetumomab pasudotox, FDA-approved 2018)
The drug
After apheresis to collect T-cells, the treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -5 to -2: fludarabine 30 mg/m2/dose. Day -3 to -2: cyclophosphamide 500 mg/m2/dose Day 0: CD22CART infusion (currently at dose level 2 [DL2]: 3 x 10^5 transduced CAR-T cells/kg). Participants will be evaluated for response at Day 28 post-CD22CART infusion and multiple time points thereafter.
Background * Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at the time of relapse.
However, many patients are now relapsed after BRAF treatment and are resistant to it. There are also patients with variant HCL (HCLv), and others with high-risk HCL lacking BRAF V600E. This includes those with BRAF wild type IGHV4-34 unmutated HCL who respond poorly to chemotherapy and have poor survival. HCLv also is brightly CD22+, sometimes resembles HCL morphologically but is more aggressive and responds poorly to standard purine analog chemotherapy. Patients have fewer options of targeted treatment partly due to wild type BRAF.
The study
Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person's T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. Researchers want to see if this treatment can help people with hairy cell leukemia (HCL). Objective: To test whether it is safe to give anti-CD22 CAR T cells to people with HCL. And also to document efficacy.
Eligibility: Adults ages 18 and older with HCL (classic or variant type) who have already had, are unable to receive, or have refused other standard treatments for their cancer. Design: Participants will be screened with the following: Medical history Physical exam Blood and urine tests Biopsy sample Electrocardiogram Echocardiogram Lung function tests Imaging scans Some screening tests will be repeated during the study.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.